Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antibodies, Monoclonal, Humanized"" wg kryterium: Temat


Tytuł :
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.
Autorzy :
Boye K; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, PO Box 4953, NO-0424, Oslo, Norway. .; Department of Tumor Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. .
Longhi A; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Guren T; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, PO Box 4953, NO-0424, Oslo, Norway.
Lorenz S; Department of Core Facilities, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Næss S; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, PO Box 4953, NO-0424, Oslo, Norway.
Pierini M; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Taksdal I; Department of Radiology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Lobmaier I; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Cesari M; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Paioli A; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Løndalen AM; Department of Nuclear Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Setola E; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.; Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Hompland I; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, PO Box 4953, NO-0424, Oslo, Norway.
Meza-Zepeda LA; Department of Tumor Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Core Facilities, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Sundby Hall K; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, PO Box 4953, NO-0424, Oslo, Norway.
Palmerini E; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Sep; Vol. 70 (9), pp. 2617-2624. Date of Electronic Publication: 2021 Feb 12.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Bone Neoplasms/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Osteosarcoma/*drug therapy
Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/metabolism ; Biomarkers, Tumor ; Bone Neoplasms/diagnosis ; Bone Neoplasms/etiology ; Bone Neoplasms/mortality ; Combined Modality Therapy ; Fluorodeoxyglucose F18 ; Gene Expression Profiling ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/adverse effects ; Neoplasm Metastasis ; Neoplasm Staging ; Osteosarcoma/diagnosis ; Osteosarcoma/etiology ; Osteosarcoma/mortality ; Positron Emission Tomography Computed Tomography ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer.
Autorzy :
Marumo Y; Nagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.; Department of Clinical Oncology, Nagoya Memorial Hospital, Nagoya, Japan.
Kusumoto S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. .
Masaki A; Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nakashima T; Nagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Kikuchi T; Nagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Mori F; Nagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Komatsu H; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Inagaki H; Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Inagaki A; Nagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Aug; Vol. 114 (2), pp. 280-285. Date of Electronic Publication: 2021 Mar 27.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Lung Neoplasms/*drug therapy
Lymphoma, Follicular/*diagnosis
Neoplasms, Second Primary/*diagnosis
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Female ; Humans ; Lung Neoplasms/diagnosis ; Lymph Nodes/pathology ; Lymphoma, Follicular/etiology ; Neoplasms, Second Primary/etiology ; Positron Emission Tomography Computed Tomography/methods
Czasopismo naukowe
Tytuł :
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
Autorzy :
Liu SN; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Lu T; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Jin JY; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Li C; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Girish S; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Melnikov F; Department of Safety Assessment, Genentech, Inc., South San Francisco, California, USA.
Badovinac Crnjevic T; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Machackova Z; PDMA-Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Restuccia E; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Kirschbrown WP; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło :
Journal of clinical pharmacology [J Clin Pharmacol] 2021 Aug; Vol. 61 (8), pp. 1096-1105. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/pharmacokinetics
Dose-Response Relationship, Drug*
Time-to-Treatment*
Trastuzumab*/administration & dosage
Trastuzumab*/pharmacokinetics
Breast Neoplasms/*drug therapy
Maintenance Chemotherapy/*methods
Receptor, ErbB-2/*antagonists & inhibitors
Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; COVID-19/epidemiology ; COVID-19/prevention & control ; Computer Simulation ; Consolidation Chemotherapy/methods ; Drug Administration Routes ; Drug Administration Schedule ; Female ; Humans ; Infection Control/methods ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost-utility analysis.
Autorzy :
Saiyarsarai P; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.; Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Robabpour Derakhshan A; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Khedmati J; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Eshghi P; Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyedifar M; Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Oct 08; Vol. 100 (40), pp. e27303.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antibodies, Bispecific/*economics
Antibodies, Monoclonal, Humanized/*economics
Factor VIIa/*economics
Hemophilia A/*drug therapy
Adult ; Antibodies, Bispecific/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Child ; Child, Preschool ; Cost-Benefit Analysis ; Factor VIIa/administration & dosage ; Female ; Hemophilia A/economics ; Hemorrhage/prevention & control ; Humans ; Iran ; Male ; Quality-Adjusted Life Years ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/economics ; Young Adult
Czasopismo naukowe
Tytuł :
Avelumab-induced lichen planopilaris, a novel association.
Autorzy :
Dominguez-Santas M; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Fernandez-Nieto D; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Diaz-Guimaraens B; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Suarez-Valle A; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Jimenez-Cauhe J; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Saceda-Corralo D; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Pokaż więcej
Źródło :
International journal of dermatology [Int J Dermatol] 2021 Oct; Vol. 60 (10), pp. e414-e416. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Letter
MeSH Terms :
Antibodies, Monoclonal, Humanized*/adverse effects
Lichen Planus*/chemically induced
Lichen Planus*/drug therapy
Humans
Opinia redakcyjna
Tytuł :
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Autorzy :
Ganesh R; Mayo Clinic, Rochester, Minnesota, USA.
Pawlowski CF; nference, Cambridge, Massachusetts, USA.
O'Horo JC; Mayo Clinic, Rochester, Minnesota, USA.
Arndt LL; Mayo Clinic Health System, Eau Claire, Wisconsin, USA.
Arndt RF; Mayo Clinic Health System, Eau Claire, Wisconsin, USA.
Bell SJ; Mayo Clinic, Rochester, Minnesota, USA.
Bierle DM; Mayo Clinic, Rochester, Minnesota, USA.
Borgen MD; Mayo Clinic, Rochester, Minnesota, USA.
Hanson SN; Mayo Clinic Health System, Mankato, Minnesota, USA.
Heyliger A; Mayo Clinic, Rochester, Minnesota, USA.
Larsen JJ; Mayo Clinic, Rochester, Minnesota, USA.
Lenehan PJ; nference, Cambridge, Massachusetts, USA.
Orenstein R; Mayo Clinic in Arizona, Phoenix, Arizona, USA.
Puranik A; nference, Cambridge, Massachusetts, USA.
Speicher LL; Mayo Clinic in Florida, Jacksonville, Florida, USA.
Tulledge-Scheitel SM; Mayo Clinic, Rochester, Minnesota, USA.
Venkatakrishnan AJ; nference, Cambridge, Massachusetts, USA.
Wilker CG; Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, USA.
Badley AD; Mayo Clinic, Rochester, Minnesota, USA.
Razonable RR; Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
The Journal of clinical investigation [J Clin Invest] 2021 Oct 01; Vol. 131 (19).
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*/drug therapy
COVID-19*/metabolism
COVID-19*/mortality
Hospitalization*
Antibodies, Monoclonal, Humanized/*administration & dosage
SARS-CoV-2/*metabolism
Administration, Intravenous ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Disease-Free Survival ; Female ; Humans ; Intensive Care Units ; Male ; Middle Aged ; Risk Factors ; Survival Rate
Czasopismo naukowe
Tytuł :
Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study.
Autorzy :
Avdeev SN; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. Electronic address: .
Trushenko NV; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Tsareva NA; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Yaroshetskiy AI; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Merzhoeva ZM; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Nuralieva GS; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Nekludova GV; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Chikina SY; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Gneusheva TY; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Suvorova OA; International School 'Medicine of the Future', I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Shmidt AE; International School 'Medicine of the Future', I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Pokaż więcej
Źródło :
Cytokine [Cytokine] 2021 Oct; Vol. 146, pp. 155627. Date of Electronic Publication: 2021 Jul 03.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*therapy
Hospitalization/*statistics & numerical data
Inpatients/*statistics & numerical data
Interleukin-17/*antagonists & inhibitors
SARS-CoV-2/*drug effects
Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; COVID-19/complications ; COVID-19/virology ; Case-Control Studies ; Diarrhea/chemically induced ; Dyspnea/chemically induced ; Female ; Humans ; Inflammation/complications ; Inflammation/drug therapy ; Interleukin-17/immunology ; Interleukin-17/metabolism ; Length of Stay/statistics & numerical data ; Male ; Middle Aged ; Pilot Projects ; Respiration, Artificial ; Retrospective Studies ; SARS-CoV-2/physiology ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19.
Autorzy :
Buryachkovskaya L; National Cardiology Research Center, 121552 Moscow, Russia.
Lomakin N; Cardiology Division, Central Clinical Hospital of Presidential Administration, 121359 Moscow, Russia.
Melkumyants A; National Cardiology Research Center, 121552 Moscow, Russia.; Institute of Physics and Technology, 141701 Moscow, Russia.
Docenko J; National Cardiology Research Center, 121552 Moscow, Russia.
Serebruany V; Neurology, Johns Hopkins University, Baltimore, MD 21794, USA.
Pokaż więcej
Źródło :
Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2021 Sep 24; Vol. 22 (3), pp. 549-551.
Typ publikacji :
Letter; Observational Study
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Blood Platelets/*drug effects
COVID-19/*drug therapy
Erythrocytes/*drug effects
Leukocytes/*drug effects
Anti-Inflammatory Agents/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Blood Platelets/ultrastructure ; COVID-19/blood ; COVID-19/diagnosis ; Case-Control Studies ; Erythrocytes/ultrastructure ; Humans ; Leukocytes/ultrastructure ; Microscopy, Electron, Scanning ; Prospective Studies ; Treatment Outcome
SCR Protocol :
COVID-19 drug treatment
Raport
Tytuł :
Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
Autorzy :
Buryachkovskaya L; National Medical Research Center of Cardiology, Moscow, Russia.
Lomakin N; Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia.
Melkumyants A; National Medical Research Center of Cardiology, Moscow, Russia.; Institute of Physics and Technology, Moscow, Russia.
Docenko J; National Medical Research Center of Cardiology, Moscow, Russia.
Serebruany V; Division of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Pokaż więcej
Źródło :
European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2021 Sep 21; Vol. 7 (5), pp. e81-e82.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
SARS-CoV-2*
Antibodies, Monoclonal, Humanized/*therapeutic use
Blood Cells/*drug effects
COVID-19/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Antibodies, Monoclonal, Humanized/pharmacology ; COVID-19/blood ; Humans
SCR Protocol :
COVID-19 drug treatment
Raport
Tytuł :
Bimekizumab versus Adalimumab in Plaque Psoriasis. Reply.
Autorzy :
Warren RB; Salford Royal NHS Foundation Trust, Manchester, United Kingdom .
Cioffi C; UCB, Raleigh, NC.
Peterson L; UCB, Raleigh, NC.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 16; Vol. 385 (12), pp. 1150.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antibodies, Monoclonal, Humanized*/therapeutic use
Psoriasis*/drug therapy
Adalimumab/therapeutic use ; Humans
Opinia redakcyjna
Tytuł :
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Autorzy :
Griffith SK; Medical College of Georgia at Augusta University, Augusta, GA.
Ahn GS; University of California, San Diego, La Jolla, CA.
Wu JJ; Dermatology Research and Education Foundation, Irvine, CA .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 16; Vol. 385 (12), pp. 1149-1150.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antibodies, Monoclonal, Humanized*/therapeutic use
Psoriasis*/drug therapy
Adalimumab/therapeutic use ; Humans
Opinia redakcyjna
Tytuł :
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Autorzy :
Luo H; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China.
Lu J; Sichuan Cancer Hospital, Chengdu, China.
Bai Y; Harbin Medical University Cancer Hospital, Harbin, China.
Mao T; Shanghai Chest Hospital, Shanghai, China.
Wang J; The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Fan Q; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang Y; Zhejiang Cancer Hospital, Hangzhou, China.
Zhao K; Fudan University Shanghai Cancer Center, Shanghai, China.
Chen Z; The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Gao S; The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China.
Li J; Fujian Provincial Cancer Hospital, Fuzhou, China.
Fu Z; 900 Hospital of the Joint Logistics Support Force, Fuzhou, China.
Gu K; The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Liu Z; Jiangxi Provincial Cancer Hospital, Nanchang, China.
Wu L; Hunan Cancer Hospital, Changsha, China.
Zhang X; Peking University Cancer Hospital and Institute, Beijing, China.
Feng J; Jiangsu Cancer Hospital, Nanjing, China.
Niu Z; Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
Ba Y; Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhang H; The Second Affiliated Hospital of Air Force Medical University, Xi'an, China.
Liu Y; Henan Cancer Hospital, Zhengzhou, China.
Zhang L; Chongqing Three Gorges Central Hospital, Chongqing, China.
Min X; Anhui Chest Hospital, Hefei, China.
Huang J; Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
Cheng Y; Jilin Cancer Hospital, Changchun, China.
Wang D; Army Medical Center of PLA, Chongqing, China.
Shen Y; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
Yang Q; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
Zou J; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
Xu RH; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Corporate Authors :
ESCORT-1st Investigators
Źródło :
JAMA [JAMA] 2021 Sep 14; Vol. 326 (10), pp. 916-925.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Esophageal Neoplasms/*drug therapy
Esophageal Squamous Cell Carcinoma/*drug therapy
Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/administration & dosage ; Double-Blind Method ; Esophageal Neoplasms/mortality ; Esophageal Squamous Cell Carcinoma/mortality ; Esophageal Squamous Cell Carcinoma/secondary ; Female ; Humans ; Immunotherapy ; Male ; Middle Aged ; Paclitaxel/administration & dosage ; Placebos ; Progression-Free Survival ; Quality of Life ; Survival Analysis
Czasopismo naukowe
Tytuł :
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks.
Autorzy :
Knopman DS; From the Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; and Department of Neurology (J.S.P.), Washington University School of Medicine, St. Louis, MO. .
Perlmutter JS; From the Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; and Department of Neurology (J.S.P.), Washington University School of Medicine, St. Louis, MO.
Pokaż więcej
Źródło :
Neurology [Neurology] 2021 Sep 14; Vol. 97 (11), pp. 545-547. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Antibodies, Monoclonal, Humanized*/adverse effects
Plaque, Amyloid*
Humans
Czasopismo naukowe
Tytuł :
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Autorzy :
Brunner HI; Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA .
Abud-Mendoza C; Unidad Regional de Reumatologia y Osteoporosis, Hospital Central and Facultad de Medicina, Universidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico.
Mori M; Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Bunkyo-ku, Japan.
Pilkington CA; Great Ormond Street Hospital for Children, London, UK.
Syed R; Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Takei S; Pediatrics and Developmental Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Viola DO; Reumatologia, Instituto CAICI, Rosario, Argentina.
Furie RA; Rheumatology, Northwell Health, Great Neck, New York, USA.
Navarra S; University of Santo Tomas, Manila, Philippines.
Zhang F; Department of Rheumatology, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China.
Bass DL; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Eriksson G; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Hammer AE; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Ji BN; GlaxoSmithKline, Brentford, UK.
Okily M; GlaxoSmithKline, Brentford, UK.
Roth DA; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Quasny H; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Ruperto N; IRCCS Istitutu Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Genova, Italy.
Pokaż więcej
Źródło :
RMD open [RMD Open] 2021 Sep; Vol. 7 (3).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized*/therapeutic use
Lupus Erythematosus, Systemic*/drug therapy
Adult ; Animals ; Bees ; Child ; Humans ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy.
Autorzy :
Magnol M; Rheumatology Department, Pierre-Paul Riquet University Hospital.
Couvaras L; Rheumatology Department, Pierre-Paul Riquet University Hospital.
Degboé Y; Rheumatology Department, Pierre-Paul Riquet University Hospital.
Delabesse E; Hematology Laboratory, CHU Toulouse.
Bulai-Livideanu C; Dermatology Department, Larrey University Hospital, Toulouse III-Paul Sabatier University, Toulouse, France.
Ruyssen-Witrand A; Rheumatology Department, Pierre-Paul Riquet University Hospital.
Constantin A; Rheumatology Department, Pierre-Paul Riquet University Hospital.
Pokaż więcej
Źródło :
Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2021 Sep 01; Vol. 60 (9), pp. e314-e315.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Hereditary Autoinflammatory Diseases/*drug therapy
Immunoglobulins, Intravenous/*administration & dosage
Interleukin-17/*antagonists & inhibitors
Spondylarthritis/*complications
Antibodies, Monoclonal, Humanized/immunology ; Hereditary Autoinflammatory Diseases/immunology ; Humans ; Immunoglobulins, Intravenous/immunology ; Interleukin-17/immunology ; Male ; Middle Aged ; Spondylarthritis/immunology
Czasopismo naukowe
Tytuł :
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.
Autorzy :
Fabrizio D; Foundation Medicine, Cambridge, USA. Electronic address: .
Cristescu R; Merck & Co, Kenilworth, USA.
Albacker L; Foundation Medicine, Cambridge, USA.
Snyder A; Merck & Co, Kenilworth, USA.
Ward A; Foundation Medicine, Cambridge, USA.
Lunceford J; Merck & Co, Kenilworth, USA.
Aurora-Garg D; Merck & Co, Kenilworth, USA.
Jin F; Merck & Co, Kenilworth, USA.
Hopkins J; Foundation Medicine, Cambridge, USA.
Rubin E; Merck & Co, Kenilworth, USA.
Hegde P; Foundation Medicine, Cambridge, USA.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Sep; Vol. 32 (9), pp. 1193-1194. Date of Electronic Publication: 2021 May 31.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Neoplasms*/drug therapy
Neoplasms*/epidemiology
Humans ; Prevalence
Opinia redakcyjna
Tytuł :
Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
Autorzy :
Destache CJ; Pharmacy Practice, Creighton University, Omaha, Nebraska, USA.
Aurit SJ; Department of Clinical Research, Creighton University, Omaha, Nebraska, USA.
Schmidt D; Pharmacy Clinical Service, CHI Health, Omaha, Nebraska, USA.
Peet Erkes L; Risk Management Operations, CHI Health (Midwest), Omaha, Nebraska, USA.
Tierney M; Medicine, Creighton University, Omaha, Nebraska, USA.
Vivekanandan R; Medicine, Creighton University, Omaha, Nebraska, USA.
Pokaż więcej
Źródło :
Pharmacotherapy [Pharmacotherapy] 2021 Sep; Vol. 41 (9), pp. 743-747. Date of Electronic Publication: 2021 Aug 12.
Typ publikacji :
Journal Article
MeSH Terms :
SARS-CoV-2*
Antibodies, Monoclonal, Humanized/*therapeutic use
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antiviral Agents/administration & dosage ; Case-Control Studies ; Cohort Studies ; Female ; Hospitalization ; Humans ; Male ; Propensity Score ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies